Outcomes for patients with late-stage mutant-IDH2 (m IDH2) relapsed/refractory acute myeloid leukemia (R/R AML) treated with enasidenib vs other lower-intensity therapies in the randomized, phase 3 IDHentify Trial
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Conference item |
Language: | English |
Published: |
American Society of Hematology
2021
|